Please assess the completion status of the following clinical trial:

Trial Title: Study to Compare the Triple ACT AL+AQ With the ACT AL in Cambodia and Vietnam

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female, aged from 2 years to 65 years old~* Acute uncomplicated P. falciparum malaria, confirmed by positive blood smear with asexual forms of P. falciparum (or mixed with non-falciparum species)~* Asexual P. falciparum parasitaemia: 16 to 200,000/microlitre, determined on a thin or thick blood film~* Fever defined as \> 37.5°C tympanic temperature or a history of fever within the last 24 hours~* Written informed consent (by parent/guardian in case of children)~* Willingness and ability of the patients or parents/guardians to comply with the study protocol for the duration of the study~Exclusion Criteria:~* Signs of severe/complicated malaria~* Haematocrit \< 25% or Hb \< 8 g/dL at screening~* Acute illness other than malaria requiring treatment~* For females: pregnancy, breast feeding~* Patients who have received artemisinin or a derivative or an artemisinin-containing combination therapy (ACT) within the previous 7 days~* History of allergy or known contraindication to artemisinins, lumefantrine or amodiaquine~* Previous splenectomy~* corrected QT interval \> 450 milliseconds at moment of presentation~* Documented or claimed history of cardiac conduction problems~* Previous participation in the current study or another study in the previous 3 months

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- ACT (Type: ACTIVE_COMPARATOR): Artemether-lumefantrine for 3 days plus primaquine at hour 24
- TACT (Type: EXPERIMENTAL): Artemether-lumefantrine for 3 days plus Amodiaquine for 3 days plus primaquine at hour 24

Based on this trial design, predict the completion outcome and termination type (if applicable).